Twentyeight-Seven Therapeutics grabs $65 mln Series A
Cambridge, Massachusetts-based Twentyeight-Seven Therapeutics, a biotech firm focused on modulating non-coding RNA biology to develop treatments for cancer and other diseases, has closed $65 million in Series A financing. MPM Capital and Novartis Venture Fund led the round with participation from other investors that included Johnson & Johnson Innovation – JJDC, Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management.
6 September 2018•1 min read
